Journal article
Targeting heart failure with preserved ejection fraction: current status and future prospects
Vascular health and risk management, v 12(Issue 1), pp 129-141
01 Jan 2016
PMID: 27143907
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Heart failure with preserved ejection fraction (HFpEF) portrays a significant burden in terms of prevalence, morbidity, mortality, and health care costs. There is a lack of consensus on the basic pathophysiology, definition, and therapeutic targets for therapy for this syndrome. To date, there are no approved therapies available for reducing mortality or hospitalization for these patients. Several clinical trials have recently started to try and bridge this major gap. There is an urgent need to focus on drug and device development for HFpEF as well as to understand HFpEF pathophysiology.
Metrics
Details
- Title
- Targeting heart failure with preserved ejection fraction: current status and future prospects
- Creators
- Manreet Kanwar - Allegheny General HospitalClaire Walter - Allegheny General HospitalMegan Clarke - Allegheny General HospitalMaria Patarroyo-Aponte - Allegheny General Hospital
- Publication Details
- Vascular health and risk management, v 12(Issue 1), pp 129-141
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Cardiology
- Web of Science ID
- WOS:000383699400001
- Scopus ID
- 2-s2.0-84964483771
- Other Identifier
- 991021932196304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Peripheral Vascular Disease